ClinicalTrials.gg
Enrolling by invitationNCT07773883Updated Nov 6, 2026

An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD

A Phase 3 interventional study of Solriamfetol in ADHD, sponsored by Axsome Therapeutics, Inc.. Enrolling by invitation at 10 sites in United States. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Updated Nov 6, 20268 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Planned enrollment
84th of 706
300 · median 70
Started
2026
with 32 others
Phase 3
121 of 807
4 open now
Primary completion
2027-12
later than 72 of 115 live
Registered
801st of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 84th largest by planned enrollment of the 706 interventional ones that give a count, is one of 33 that started in 2026, is one of 121 in phase 3, reaches primary completion later than 72 of the 115 other live ones, and was the 801st registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

This study is a Phase 3, multi-center, open-label trial to evaluate the long-term safety of solriamfetol in children and adolescents with ADHD.

Read the detailed description

Eligible subjects are children and adolescents with ADHD who have completed either Study SOL-ADHD-302 (FOCUS-2) or Study SOL-ADHD-304 (FOCUS-3). Subjects will be assigned to age-based cohorts and will receive solriamfetol once daily for up to 52 weeks.

03

Conditions studied

  • ADHD

Keywords

  • Attention deficit hyperactivity disorder
  • ADHD
  • Sunosi
  • Solriamfetol
  • Axsome
  • Non-stimulant therapy
  • Dopamine norepinephrine reuptake inhibitor
  • Trace amine-associated receptor 1 (TAAR1) agonist
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed Study SOL-ADHD-302 (FOCUS-2) or Study SOL-ADHD-304 (FOCUS-3).
  • Has a parent/legal guardian to provide written and/or is willing to provide written informed assent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Solriamfetol

    Up to 52 weeks

    Drug: Solriamfetol

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment-Emergent Adverse Events (TEAEs)

    An AE is defined as treatment emergent if the first onset or worsening is after the first administration of the study drug and not more than 7 days after the last dose of study drug or 30 days after the last dose of study drug for SAEs.

    Time frame: Up to 52 weeks

07

Study locations

10 sites
  • Clinical Research Site
    Dothan, Alabama 36303, United States
  • Clinical Research Site
    Little Rock, Arkansas 72211, United States
  • Clinical Research Site
    Coral Gables, Florida 33146, United States
  • Clinical Research Site
    Jacksonville, Florida 32256, United States
  • Clinical Research Site
    Maitland, Florida 32751, United States
  • Clinical Reseach Site
    Orlando, Florida 32801, United States
  • Clinical Research Site
    Jackson, Mississippi 39206, United States
  • Clinical Research Site
    Staten Island, New York 10314, United States
  • Clinical Research Site
    North Charleston, South Carolina 29405, United States
  • Clinical Research Site
    Memphis, Tennessee 38119, United States
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's planned 16 months is above that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Aug 19, 2026
StartActual
Aug 6, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added, 1 site removed
Show 8 added (8 United States)
  • Clinical Research Site · Little Rock, United States
  • Clinical Research Site · Jacksonville, United States
  • Clinical Research Site · Orlando, United States
  • Clinical Research Site · North Charleston, United States
  • Clinical Research Site · Coral Gables, United States
  • Clinical Reseach Site · Orlando, United States
  • Clinical Research Site · Jackson, United States
  • Clinical Research Site · Staten Island, United States
Show 1 removed
  • Clinical Research Site · Orlando, United States
across 2 updates, Oct 13, 2026 – Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    4 sites added, 1 site removed
    Show 4 added (4 United States)
    • Clinical Research Site · Coral Gables, United States
    • Clinical Reseach Site · Orlando, United States
    • Clinical Research Site · Jackson, United States
    • Clinical Research Site · Staten Island, United States
    Show 1 removed
    • Clinical Research Site · Orlando, United States
    + 1 other change: verification date
  2. Oct 13, 2026
    4 sites added
    Show 4 added (4 United States)
    • Clinical Research Site · Little Rock, United States
    • Clinical Research Site · Jacksonville, United States
    • Clinical Research Site · Orlando, United States
    • Clinical Research Site · North Charleston, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07773883
Responsible party
Sponsor
First posted
Aug 19, 2026
Start date
Aug 6, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion